Ensysce Biosciences, Inc. ENSC
Set alert
At close · Oct 30
After hours · Oct 30, 6:13 PM ET
- YTD
- -54.24%
- 1 year
- -80.51%
- Open
- 0.427
- Prev close
- 0.438
- Mkt cap
- 8.19M
- Vol
- 108.95K
- Avg vol
- 13.97M
- EPS
- -2.47
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.42
- High
- 0.44
- Forward P/E
- -9.08
- Beta
- 0.64
- Short ratio
- 0.12
- Inst. own
- 22.26%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 7.25
- 200-d avg
- 7.64
- 1y target
- 102.00
News
1 week ago accessnewswire.com
Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai
~President James Morrison met Middle East family offices as Ensysce advances CY200 and its severe pain pipeline~ SAN DIEGO, CA / ACCESS Newswire / October 21, 2026 / Ensysce Biosciences, Inc.…
-
1 week ago benzinga.com
Cantor Fitzgerald Initiates Coverage On Ensysce Biosciences with Overweight Rating, Announces Price Target of $2
Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Ensysce Biosciences (NASDAQ:ENSC) with a Overweight rating and announces Price Target of $2.
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 13.3% to $0.55 during Wednesday's after-market session. Impact BioMedical (AMEX:IBO) stock rose 10.77% to $3.77. The company's market cap…
1 month ago defenseworld.net
Contrasting Hypermarcas (OTCMKTS:HYPMY) and Ensysce Biosciences (NASDAQ:ENSC)
Ensysce Biosciences (NASDAQ: ENSC - Get Free Report) and Hypermarcas (OTCMKTS:HYPMY - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two…
1 month ago accessnewswire.com
Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA
~ Submission to the UK MHRA for review marks critical step towards initiating a Phase 2 Study with CY200 ~ SAN DIEGO, CA / ACCESS Newswire / September 24, 2026 / Ensysce Biosciences, Inc.…
1 month ago accessnewswire.com
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation
SAN DIEGO, CA / ACCESS Newswire / September 15, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic…
1 month ago accessnewswire.com
Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs
SAN DIEGO, CA / ACCESS Newswire / September 14, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic…
2 months ago accessnewswire.com
Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation
SAN DIEGO, CA / ACCESS Newswire / September 2, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") a clinical-stage biotechnology company developing novel neuroplastogenic…
-
2 months ago benzinga.com
Ensysce Biosciences Completes Enrollment In Final Stage Of PF614-MPAR-102 Clinical Study
~ ~ The Second Study Fully Enrolled for Breakthrough Therapy-Designated, First-in-Class Opioid Designed to Protect Against Oral Overdose ~ ~SAN DIEGO, CA / ACCESS Newswire / August 31, 2026 / Ensysce…
2 months ago accessnewswire.com
Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study
~ ~ The Second Study Fully Enrolled for Breakthrough Therapy-Designated, First-in-Class Opioid Designed to Protect Against Oral Overdose ~ ~ SAN DIEGO, CA / ACCESS Newswire / August 31, 2026 /…
2 months ago accessnewswire.com
Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium
~Major symposium to highlight breakthrough innovations in severe pain and Complex Regional Pain Syndrome (CRPS) ~ ~Discussions to feature a first-in-class approach to neural reset and novel chemical…
2 months ago seekingalpha.com
Ensysce Biosciences, Inc. (ENSC) Discusses Acquisition of Cy Biopharma and Private Placement Financing Prepared Remarks Transcript
Ensysce Biosciences, Inc. (ENSC) Discusses Acquisition of Cy Biopharma and Private Placement Financing Prepared Remarks Transcript
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers iTonic Holdings (NASDAQ:ITOC) stock moved upwards by 32.0% to $0.41 during Friday's after-market session. The company's market cap stands at $4.9 million. Quanterix (NASDAQ:QTRX) shares…
-
2 months ago benzinga.com
Ensysce Biosciences Q2 EPS $(0.20) Beats $(0.50) Estimate, Sales $1.164M Beat $1.000M Estimate
Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.50) by 60 percent. This is a 74.68 percent increase over losses of…
2 months ago accessnewswire.com
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Acquisition of Cy Biopharma Completed, Adding CY200 for Complex Regional Pain Syndrome Up to $77 million in new funding with the acquisition of Cy Biopharma Company to host a Corporate Update Call on…
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 48.4% to $0.16 during Thursday's regular session. The market value of their outstanding shares is at $7.2 million. BeyondSpring (NASDAQ:BYSI)…
2 months ago defenseworld.net
Ensysce Biosciences (NASDAQ:ENSC) versus CannAmerica Brands (OTCMKTS:CNNXF) Head to Head Review
Ensysce Biosciences (NASDAQ: ENSC - Get Free Report) and CannAmerica Brands (OTCMKTS:CNNXF - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday's regular session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
2 months ago benzinga.com
Nasdaq Down 50 Points; US Foods Posts Upbeat Earnings
US stocks trade mixed, Nasdaq falls 50 points. Energy shares up 1.3%, tech stocks down 0.5%. US Foods beats earnings, Clearone Inc surges 203%.
-
2 months ago benzinga.com
Ensysce Biosciences Completes Acquisition Of Cy Biopharma, Secures $17.1M Cash Financing And $21.5M Series C Preferred Stock Private Placement With Potential $38.6M Follow-On Tranche To Fund CY200 Development Through 2028
Acquisition includes clinical-stage neuroplastogenic therapy with U.S. FDA Orphan Drug Designation for the treatment of Complex Regional Pain Syndrome (CRPS)Up to $77 million in private financing…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's pre-market session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
2 months ago accessnewswire.com
Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing
Acquisition includes clinical-stage neuroplastogenic therapy with U.S. FDA Orphan Drug Designation for the treatment of Complex Regional Pain Syndrome (CRPS) Up to $77 million in private financing…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 415.3% to $18.81 during Tuesday's regular session. The company's market cap stands at $1.9 million. Adagio Medical Holdings (NASDAQ:ADGM) shares…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock moved upwards by 55.4% to $0.44 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. Adagio Medical Holdings…
2 months ago benzinga.com
Why Palantir Shares Are Trading Higher By 16%; Here Are 20 Stocks Moving Premarket
Palantir Technologies Inc (PLTR) shares jumped 16.1% in pre-market trading on upbeat Q2 results, with revenue of $1.94B and EPS of 41 cents. Other gainers include RAIN, ENSC, ELPW, DXST, ADGM, AMRC,…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock rose 118.1% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $3.8 million. TransCode Therapeutics…
-
3 months ago benzinga.com
Ensysce Biosciences Has Received A Notice Of Allowance For A U.S. Patent Titled "COMPOSITIONS COMPRISING ENZYME-CLEAVABLE AMPHETAMINE PRODRUGS AND INHIBITORS THEREOF".
https://x.com/PatentGrants/status/2084367854472954161https://patentcenter.uspto.gov/applications/17436041/ifw/docs
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers NextCure (NASDAQ:NXTC) shares rose 305.5% to $8.84 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.8 million. Shuttle Pharmaceuticals (NASDAQ:SHPH)…
3 months ago accessnewswire.com
Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant
Funds Advance FDA-Designated Breakthrough Therapy First-in-Class Opioid with Oral Overdose-Protection SAN DIEGO, CA / ACCESS Newswire / July 14, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC)…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Seer (NASDAQ:SEER) stock moved upwards by 33.3% to $2.16 during Thursday's after-market session. The market value of their outstanding shares is at $89.6 million. Universe Pharmaceuticals…
4 months ago accessnewswire.com
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
~ ~ Advances First-in-Class, Breakthrough Therapy-Designated Opioid Engineered to Protect Against Oral Overdose ~ ~ SAN DIEGO, CA / ACCESS Newswire / June 26, 2026 / Ensysce Biosciences, Inc.…
5 months ago accessnewswire.com
Ensysce Biosciences Reports First Quarter 2026 Financial Results
~ IRB Approval Secured for PF614-MPAR-102 Part 3 ~ ~ Clinical Peer-Reviewed Data Published for First Overdose Protected Opioid PF614-MPAR®; Patent Estate Expanded ~ ~ Company Launches Formal Review…
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
5 months ago accessnewswire.com
Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
~ Patent Extends Jurisdiction and Protection Through 2042 ~ SAN DIEGO, CA / ACCESS Newswire / May 12, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage…
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
5 months ago accessnewswire.com
Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam
~ Chemical Control, Clinical Confidence: Rethinking Opioids ~ SAN DIEGO, CA / ACCESS Newswire / May 8, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage…
6 months ago accessnewswire.com
Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study
~ Advances First-in-Class Opioid with Oral Overdose-Protection ~ SAN DIEGO, CA / ACCESS Newswire / April 16, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
6 months ago accessnewswire.com
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs
~Continued funding underscores investor confidence and supports advancement of abuse- and overdose-resistant analgesics~ SAN DIEGO, CA / ACCESS Newswire / April 7, 2026 / Ensysce Biosciences, Inc.…
7 months ago accessnewswire.com
Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results
~ Fourth Quarter Highlighted by Clinical and Regulatory Milestones Positioning PF614 for Late-Stage Advancement ~ SAN DIEGO, CA / ACCESS Newswire / March 30, 2026 / Ensysce Biosciences, Inc.…
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
8 months ago benzinga.com
10 Health Care Stocks Moving In Monday's Pre-Market Session
10 Health Care Stocks Moving In Monday's Pre-Market Session
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Friday's Intraday Session
8 months ago benzinga.com
Dow Dips Over 600 Points; US Producer Prices Increase In January
US stocks traded lower, Dow down 600 points. Nasdaq and S&P also fell. Consumer staples up, tech down. Producer prices rose in January.
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
8 months ago benzinga.com
Why Applied Optoelectronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Why Applied Optoelectronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session